Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1169596 Target Snapshot

Serine/threonine-protein kinase A-Raf · SINGLE PROTEIN · Homo sapiens

413Compounds
90Assays
5Approved Drugs
346.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Serine/threonine-protein kinase A-Raf shows clinical signal disease relevance led by colorectal neoplasm. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P10398. Start with colorectal neoplasm, then reuse UniProt P10398 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with colorectal neoplasm, then reuse UniProt P10398 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
colorectal neoplasm

Serine/threonine-protein kinase A-Raf shows clinical signal disease relevance led by colorectal neoplasm. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with colorectal neoplasm because it currently carries clinical signal support. Linked drugs include LY-3009120. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase A-Raf as ChEMBL target CHEMBL1169596, mapped to UniProt P10398. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase A-Raf
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1169596
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P10398
Serine/threonine-protein kinase A-Raf
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase A-Raf is the right protein anchor across sources, using UniProt P10398 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why colorectal neoplasm is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase A-Raf
UniProt AccessionP10398
Component TypeProtein
Sequence Length606 aa

Serine/threonine-protein kinase A-Raf

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase A-Raf, mapped to UniProt P10398. Sequence length is 606 aa.

Mapped IDP10398
Review nameSerine/threonine-protein kinase A-Raf
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Serine/threonine-protein kinase A-Raf shows clinical signal disease relevance led by colorectal neoplasm. 3 more disease programs remain visible in the same review block.

Clinical signal Phase I
colorectal neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugLY-3009120
Clinical signal Phase I
melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugLY-3009120
Clinical signal Phase I
metastasis
1 linked drug · 1 direct · 1 efficacy
Linked drugLY-3009120
Clinical signal Phase I
non-small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugLY-3009120
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with colorectal neoplasm because it currently carries clinical signal support. Linked drugs include LY-3009120. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecolorectal neoplasm
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
1
Phase III
5
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC50111.0
KD235.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4466555 9.0 IC50 1.0 Preclinical
CHEMBL3577124 8.92 IC50 1.2 Preclinical
CHEMBL1229517 8.68 IC50 2.1 Approved
CHEMBL5095099 8.62 IC50 2.4 Clinical
CHEMBL4207519 8.25 IC50 5.6 Preclinical
CHEMBL1336 8.15 IC50 7.1 Approved
CHEMBL4438236 8.07 IC50 8.6 Preclinical
CHEMBL1880739 7.84 IC50 14.6 Preclinical
CHEMBL4060057 7.75 IC50 17.8 Preclinical
CHEMBL4075036 7.6 IC50 25.3 Preclinical
Distribution

pChEMBL Value Distribution

2
5.0
4
5.5
2
6.0
7
6.5
12
7.0
8
7.5
4
8.0
4
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

DABRAFENIB
CHEMBL2028663
Approved 2013
VEMURAFENIB
CHEMBL1229517
Approved 2011
SORAFENIB
CHEMBL1336
Approved 2005
Assay Landscape

Assay Landscape

90
Total Assays
40
Tested Compounds
1
Assay Types
Binding — 90 assays, 40 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 72 30 7.4
cell-based format 12 6 6.9
subcellular format 6 4 5.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine